Qualitative Concept
Roche’s Genentech builds autoimmune Repertoire with deal worth up to $765M
Repertoire, genentech, Autoimmune Diseases, Immune Medicines, Partnership
Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan
Cobenfy, Schizophrenia, Antipsychotic Agents, Adjunctive Orthodontic Procedure, Myers, Statistical Significance, Improvement, Single Agent Therapy
HR25: LifeSignals launches cardiac monitoring patch to compete with iRhythm, Philips
Preventive monitoring, Plaque (lesion), Philips, Heart, iRhythm, LifeSignals, Medical Devices
New NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities
United States National Institutes of Health, recipients, NIH, Policy, Diversity, Changing, Condition, civil, federal, civil, protections, recipients, Israeli (population group), Civil Rights Act, 1964
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration
Dupixent notches seventh disease approval with urticaria nod
Dupixent, Chronic Spontaneous Urticaria, Approved, Urticaria, United States Food and Drug Administration, seventh
Chinese CRO GemPharmatech expands in San Diego as industry weighs FDA’s animal testing shift
United States Food and Drug Administration, GemPharmatech, Contract Research Organization, San Diego, Animal Testing, mouse models, expansion, Industry
FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD
United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy
FDA moves to block biopharma employees from serving on advisory committees
United States Food and Drug Administration, Workers, Advisory Committees, Industry, Policy